We also observed upregulated expression of genes encoding major histocompatibility complex (MHC) class I and II molecules (HLA-A, B, G, DMA) as well as genes encoding peptide transporter (Tap1), transporter-MHC interactions (TAPBP) and processor of MHC class I T cell epitopes (PSMB9) in the combined inhibitor treatment groups suggesting that combined PARP and WEE1 inhibition can increase tumour antigen presentation capabilities of TNBC (Supplementary Fig. 1f). This evidence concerns the gene TAPBP and neoplasm.